Navigation Links
Albuferon in Medical News

HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C

ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced the final results of a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatit...

HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C

ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the final quality-of-life results from a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...Drugs in Select Countries (includes corresponding Graph/Chart) II-3 albuferon - Rising Above the Standards II-4 Viramidine - Next-Generation Ribaviri...s with GI-5005 II-57 Human Genome Gets Encouraging Interim Results with albuferon II-58 Intarcia Releases Study Results of Omega Interferon II-58 Nau...

Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)

... of required injections. As a result, the value of HGSI shares was reduced by 57% the day the study data was released. I can't help but wonder how albuferon might have performed in combination with our Hemopurifier(R)? Regardless, a drug candidate wishing to supplant SOC therapy in the market will need to...

Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors

...ducts may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. SAFE HARBOR STATEMENT This announcement contains forward-looking statements within ...
Albuferon in Medical Technology

Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon

- Albuferon 900-mcg dosed every two weeks achieved an SVR rate at least comparable to Pegasys dosed every week (ITT analysis), with more favorable quality-of-life scores - ROCKVILLE, Md., June 07, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced the top-line final results...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the submission of global marketing applications is expected in fall 2009. BENLYSTA successfully met its pr...

Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)

...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing a... (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. SAFE ...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

...as many injections, in two pivotal Phase 3 trials, albuferon (albinterferon alfa-2b) met the primary efficacy e...eron alfa-2a) - - Patients receiving 900-mcg albuferon had comparable rates of serious and/or severe adve... the half-life of the therapeutic proteins. albuferon is being developed by HGS and Novartis for the tre...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

... - 900-mcg albuferon (albinterferon alfa-2b) dosed every two weeks met ...c hepatitis C - - Patients receiving 900-mcg albuferon had comparable rates of serious and/or severe adve...Pegasys) in ACHIEVE 1, a Phase 3 clinical trial of albuferon in combination with ribavirin in treatment-naive p...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

...e reported our company's first Phase 3 results for albuferon in chronic hepatitis C, and the data were positive. We will have results of the second albuferon Phase 3 trial in March 2009, and the results of ou...or 2008 included $35.4 million recognized from the albuferon agreement with Novartis, and $6.5 million in reven...

Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile

...an Electronic Press Kit on this announcement, please click here: http://www.firstlinemedia.com/epk/hgs/ . HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking st...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... that the results of ACHIEVE 2/3 demonstrated that albuferon (albinterferon alfa-2b) met its primary endpoint o...ic response was comparable for the 900-mcg dose of albuferon administered every two weeks, vs. the standard 180...e. The results of ACHIEVE 1, the Phase 3 trial of albuferon in genotype 1 chronic hepatitis C, are expected in...

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

...ted from spam bots, you need JavaScript enabled to view it or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking statements within ...

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

...ducts may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking statements within ...
Albuferon in Biological Technology

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has successfully completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. BENLYSTA has successfully m...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are o...

Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)

...cted by Novartis evaluating safety and efficacy of albuferon administered every four weeks in combination with ...ients with genotypes 2 and 3 chronic hepatitis C. albuferon is being developed by HGS and Novartis under an ex...on a weekly basis. A monthly dosing schedule with albuferon may well result in more patients choosing to be tr...

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are o...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... - Positive results for second Phase 3 trial of albuferon (R) in chronic hepatitis C; global marketing ap...ved our first product sales with ABthrax, and both albuferon and LymphoStat-B(R) continued to make excellent pr...e results from the second of two pivotal trials of albuferon in chronic hepatitis C, and we plan global marketi...

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing a... (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. HGS ...

Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes

...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon successfully met its primary endpoint in the first of two Phase 3 trials in chronic hepatitis C; results of the second albuferon Phase 3 trial are expected in March 2009. Two Phase 3 clinical trials of L...

Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C

...ted by Novartis to evaluate safety and efficacy of albuferon administered every four weeks in combination with ...ients with genotypes 2 and 3 chronic hepatitis C. albuferon is being developed by HGS and Novartis under an ex...ctions." In December 2008, HGS announced that albuferon met its primary endpoint of non-inferiority to peg...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

... - albuferon (albinterferon alfa-2b) met its primary endpoint o...patitis C - - Patients receiving 900-mcg albuferon had comparable rates of serious adverse events, se...gasys) in ACHIEVE 2/3, a Phase 3 clinical trial of albuferon in combination with ribavirin in treatment-naive p...

Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments

... are on track to report our first Phase 3 data for albuferon in December 2008. We are on track to report our fi...emains on track to have the first Phase 3 data for albuferon - from the ACHIEVE 2/3 trial - in December 2008. A...nsion 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sc...
Other Tags
(Date:2/27/2015)... (PRWEB) February 27, 2015 Muscular ... of Biomedical Engineering at Duke University, recently announced ... boys and young men with Duchenne muscular dystrophy ... Nature Communications, and Gersbach will discuss their implications ... March 11-14 in Washington, D.C. , Background: ...
(Date:2/27/2015)... York, NY (PRWEB) February 27, 2015 Ticket ... Tickets for his "Forest Hills Drive Tour Act 3: ... album "2014 Forest Hills Drive" which debuted on the charts ... hip-hop album. In March, this accomplished hip-hop artist will ... in early March and will visit cities such as San ...
(Date:2/27/2015)... Over 440,000 patients die each year as ... to educate readers on how they can take control of ... as a guide to educate and inspire readers to learn ... ones safe with tips on topics ranging from hospital to ... of the print publication. He recently spoke to Mediaplanet ...
(Date:2/27/2015)... 27, 2015 Lyophilization has important applications ... as a standard process to stabilize, store and increase ... molecules such as vaccines, antibodies, proteins, enzymes, hormones, ... structure. The global freeze drying market was valued at ... at $2,655.9 million by 2019 at a CAGR of ...
(Date:2/27/2015)... With cases of head lice on ... to school administrations to help prevent the spread of head ... a common parasite that passes easily among children and teens, ... teachers significant distress. , The answer may be found ... This would allow parents and teachers to immediately discover who ...
Breaking Medicine News(10 mins):Health News:Statement: New MDA-Funded Genetic Therapy Technique Targets DMD 2Health News:J. Cole Tickets in Los Angeles, Mountain View, Chula Vista, New York, Chicago, Indianapolis, Holmdel, Dallas, Seattle, Camden, Bristow, Atlanta, Houston & Detroit On Sale 2Health News:J. Cole Tickets in Los Angeles, Mountain View, Chula Vista, New York, Chicago, Indianapolis, Holmdel, Dallas, Seattle, Camden, Bristow, Atlanta, Houston & Detroit On Sale 3Health News:Safe and Sound: Improving Patient Outcomes through Mediaplanet’s “Patient Safety” Campaign 2Health News:Lyophilization Equipment Market worth $2,655.9 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Lyophilization Equipment Market worth $2,655.9 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:South Florida Parents Put Pressure on Schools to Perform Lice Screenings to Prevent Spread of Lice According to One Miami Lice Removal Company Called Lice Troopers 2
(Date:2/25/2015)... 2015  ABC Financial Services (ABC), the leading ... and Fitness Industry, today announced enhancements to their ... latest upgrade includes advances to the agreement section ... via Identity One fingerprint biometrics. The features will ... displays at the International Health, Racquet & Sportsclub ...
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:2/24/2015)... -- This report analyzes the worldwide markets for Face and Voice ... Voice Biometrics. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Latin America . Annual estimates and forecasts are ... analysis is provided for these markets. Market data and analytics are ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
Other Contents